1. Home
  2. GLAD vs EYPT Comparison

GLAD vs EYPT Comparison

Compare GLAD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLAD
  • EYPT
  • Stock Information
  • Founded
  • GLAD 2001
  • EYPT 1987
  • Country
  • GLAD United States
  • EYPT United States
  • Employees
  • GLAD N/A
  • EYPT N/A
  • Industry
  • GLAD Finance/Investors Services
  • EYPT Biotechnology: Laboratory Analytical Instruments
  • Sector
  • GLAD Finance
  • EYPT Industrials
  • Exchange
  • GLAD Nasdaq
  • EYPT Nasdaq
  • Market Cap
  • GLAD 571.4M
  • EYPT 579.4M
  • IPO Year
  • GLAD N/A
  • EYPT 2005
  • Fundamental
  • Price
  • GLAD $27.41
  • EYPT $9.66
  • Analyst Decision
  • GLAD Hold
  • EYPT Strong Buy
  • Analyst Count
  • GLAD 1
  • EYPT 8
  • Target Price
  • GLAD $23.00
  • EYPT $24.75
  • AVG Volume (30 Days)
  • GLAD 75.1K
  • EYPT 772.8K
  • Earning Date
  • GLAD 08-06-2025
  • EYPT 08-06-2025
  • Dividend Yield
  • GLAD 7.25%
  • EYPT N/A
  • EPS Growth
  • GLAD 17.67
  • EYPT N/A
  • EPS
  • GLAD 3.93
  • EYPT N/A
  • Revenue
  • GLAD $92,932,000.00
  • EYPT $56,042,000.00
  • Revenue This Year
  • GLAD N/A
  • EYPT N/A
  • Revenue Next Year
  • GLAD $12.10
  • EYPT N/A
  • P/E Ratio
  • GLAD $6.95
  • EYPT N/A
  • Revenue Growth
  • GLAD N/A
  • EYPT 12.04
  • 52 Week Low
  • GLAD $21.40
  • EYPT $3.91
  • 52 Week High
  • GLAD $30.43
  • EYPT $13.99
  • Technical
  • Relative Strength Index (RSI)
  • GLAD 63.58
  • EYPT 61.95
  • Support Level
  • GLAD $26.22
  • EYPT $8.96
  • Resistance Level
  • GLAD $27.33
  • EYPT $10.77
  • Average True Range (ATR)
  • GLAD 0.49
  • EYPT 0.77
  • MACD
  • GLAD 0.03
  • EYPT -0.02
  • Stochastic Oscillator
  • GLAD 96.36
  • EYPT 60.78

About GLAD Gladstone Capital Corporation

Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.

About EYPT EyePoint Pharmaceuticals Inc.

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Share on Social Networks: